



**Regd. Office :** 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.

**Factory :** Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.

**Contact No. :** +91 9820201063 / 8080333319 / 8411879521

**Email :** influxhealthtech@gmail.com/ influxhealthcare1@gmail.com

**Website :** www.influxhealthtech.com

**CIN :** U24299MH2020PLC346825

**April 1, 2026**

To,  
Listing Department,  
**National Stock Exchange Limited**  
Exchange Plaza, C-1, Block-G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai-400 051

**Scrip Code - INFLUX**

Dear Sir/Ma'am,

**Sub: Postal Ballot Notice – Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 30 of the SEBI (LODR) Regulations 2015, we hereby enclose the Notice of Postal Ballot dated April 1, 2026 for seeking approval through e-voting for the following resolutions:

<b>Sr. No.</b>	<b>Particulars</b>	<b>Type of resolution</b>
1.	Alteration in the objects of the Initial Public Offer (“offer”) for which amount was raised.	Special Resolution
2.	Appointment and approval of Sitting Fees of Mr. Mohmad Saleh Mutvalli (DIN: 07361078) as Independent Director of the Company.	Special Resolution

In compliance with the relevant circulars issued by the Ministry of Corporate Affairs (“MCA”) from time to time, the Notice of Postal Ballot is being sent by electronic mode only to those Members whose names appear in the Register of Members / List of Beneficial Owners and whose e-mail addresses are registered with the Company/Company’s Registrar and Share Transfer Agent/Depositories as on the “**Cut-off Date**” i.e. **Friday, March 27, 2026**.

The Company has engaged the services of CDSL for the purpose of providing e-voting facility to all its members. The remote e-voting facility would be available during the following period:

<b>Commencement of e-voting:</b>	Thursday, April 2, 2026 at 9:00 AM (IST)
<b>End of e-voting:</b>	Friday, May 1, 2026 at 5:00 PM (IST)



**Regd. Office :** 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.

**Factory :** Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.

**Contact No. :** +91 9820201063 / 8080333319 / 8411879521

**Email :** influxhealthtech@gmail.com/ influxhealthcare1@gmail.com

**Website :** www.influxhealthtech.com

**CIN :** U24299MH2020PLC346825

---

The above information will be made available on the website of the Company at [www.influxhealthtech.com](http://www.influxhealthtech.com).

We request you to take the above information on record.

Thanking you,

Yours Faithfully,

**For Influx Healthtech Limited,**

---

**Munir Abdul Ganee Chandniwala**

**Managing Director**

**DIN: 08459582**



**Regd. Office :** 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.

**Factory :** Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.

**Contact No. :** +91 9820201063 / 8080333319 / 8411879521

**Email :** influxhealthtech@gmail.com / influxhealthcare1@gmail.com

**Website :** www.influxhealthtech.com

**CIN :** U24299MH2020PLC346825

## **NOTICE OF POSTAL BALLOT**

*(Pursuant to Sections 108 and 110 of the Companies Act, 2013 read with Rules 20 and 22 of Companies (Management and Administration) Rules, 2014)*

**To,  
The Member(s),  
Influx Healthtech Limited**

**NOTICE** is hereby given to the members of Influx Healthtech Limited (the “Company”) pursuant to the provisions of Sections 108, 110 and all other applicable provisions of the Companies Act, 2013 read with the Companies (Management and Administration) Rules, 2014 (collectively the “Act”, which shall include any statutory modifications, amendments or reenactments thereto) read with General Circular Nos. 14/2020 dated April 08, 2020, 17/2020 dated April 13, 2020, 22/2020 dated June 15, 2020, 33/2020 dated September 28, 2020, 39/2020 dated December 31, 2020, 10/2021 dated June 23, 2021, 20/2021 dated December 08, 2021, 03/ 2022 dated May 05, 2022, 11/2022 dated December 28, 2022, 09/2023 dated September 25, 2023, 09/2024 dated September 19, 2024, and 03/2025 dated September 22, 2025 (“MCA Circulars”), Government of India (the “MCA Circulars”), Secretarial Standard-2 on General Meetings (“SS-2”) issued by the Institute of Company Secretaries of India (as amended from time to time), Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “Listing Regulations”) and any other applicable law, rules and regulations (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), read with the equity listing agreement executed with the stock exchange on which the equity shares of the Company are listed, for seeking approval of the shareholders by way of special resolution for matters as considered in the Resolution(s) appended below through postal ballot (“Postal Ballot”) by way of e-voting only.

The explanatory statement pertaining to the said resolution setting out the material facts and the rationale thereof is annexed hereto for your consideration and forms an integral part of this Postal Ballot Notice.

This Postal Ballot Notice is being sent in electronic form to those Members, whose names appear in the List of Beneficial Owners as on Friday, March 27, 2026 (“Record Date”) as received from Maashitla Securities Private Limited, the Registrar and Share Transfer Agent (“RTA”) of the Company and whose e-mail addresses are registered with the Depositories. In compliance with the provisions of Section 108 and Section 110 of the Act read with Rule 20 and 22 of the Rules, Regulation 44 of the Listing Regulations, and SS-2, the Company is pleased to provide e-voting facility to its Members, to enable them to cast their votes electronically. The detailed procedure with respect to e-voting is mentioned in this Notice. The Company has engaged the services of Central Depository Services (India) Limited (hereinafter referred to as “CDSL”) for facilitating e-voting. The Company has made necessary arrangements with RTA to enable the Members to register their e-mail address. Those Members who have not yet registered their e-mail address are requested to register the same by following the procedure set out in this Postal Ballot Notice.

The Board of Directors of the Company has appointed Mr. Sumitkumar Hareshbhai Patel (/Membership No.: ACS 71431), Partner of M/s. Richi Prerak & Associates, Practicing Company Secretary, as the Scrutinizer (“Scrutinizer”) for conducting the Postal Ballot / e-voting process in a fair and transparent manner.



**Regd. Office :** 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.

**Factory :** Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.

**Contact No. :** +91 9820201063 / 8080333319 / 8411879521

**Email :** influxhealthtech@gmail.com/ influxhealthcare1@gmail.com

**Website :** www.influxhealthtech.com

**CIN :** U24299MH2020PLC346825

Members desiring to exercise their vote through the e-voting process are requested to carefully read the instructions indicated in this Notice and record their assent (FOR) or dissent (AGAINST) by following the procedure as stated in the Notes forming part of the Notice.

**The votes can be cast during the following voting period:**

<b>REMOTE E-VOTING STARTS ON</b>	<b>REMOTE E-VOTING ENDS ON</b>
Thursday, April 2, 2026 at 9:00 AM (IST)	Friday, May 1, 2026 at 5:00 PM (IST)

The e-voting facility will be disabled by CDSL immediately thereafter and will not be allowed beyond the said date and time. The Scrutinizer will submit his report to the Chairman of the Company (the “Chairman”) or any other person authorized by the Chairman, and the result of the voting by Postal Ballot will be announced on or before May 5, 2026.

The results of the postal ballot (including voting through electronic means) along with the Scrutinizer’s report will be made available on the website of the Company at [www.influxhealthtech.com](http://www.influxhealthtech.com) and intimated to the stock exchange, where the shares of the Company are listed, on May 2, 2026.

The last date of e-voting, i.e. May 1, 2026, shall be the date on which the resolutions would be deemed to have been passed, if passed by the requisite majority.

The proposed resolutions, if approved, will be taken as having duly passed on the last date specified for e-voting by the requisite majority of Members by means of Postal Ballot, i.e. May 1, 2026.

**SPECIAL BUSINESS:**

**ITEM NO. 1:**

**ALTERATION IN THE OBJECTS OF THE INITIAL PUBLIC OFFER (“OFFER”) FOR WHICH AMOUNT WAS RAISED:**

*To consider, and if thought fit, to pass, with or without modifications, the following resolution as a **Special Resolution:***

**“RESOLVED THAT** pursuant to the provisions of Section 13(8) and Section 27 of the Companies Act, 2013 read with the rules made thereunder, including Rule 7 of the Companies (Prospectus and Allotment of Securities) Rules, 2014, Rule 32 of Companies (Incorporation Rules), 2014 and other applicable provisions of the Companies Act, 2013, Regulation 32 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, and all other necessary applicable provisions under the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, each as amended from time to time and subject to the necessary approvals, if any required, the consent of the Members of the Company be and is hereby accorded to vary the terms of utilization of the proceeds raised pursuant to the Initial Public Offer (IPO) of the Company as disclosed in the Prospectus dated June 23, 2025, including:

- a) reallocation of funds from the objects “Construction related expenses for Plot No. 28” and “Purchase of Machineries” towards “Construction related expenses for Plot No. 59”; and
- b) engagement of revised / alternative vendors for execution of construction related works for Plot No. 59 and Plot No. 28 in addition of the vendors disclosed in the Prospectus.

**RESOLVED FURTHER THAT** the consent of the Members be and is hereby accorded for reallocation of IPO proceeds in the following manner:

*(₹ in Lakhs)*

Division	As per Prospectus	Utilised till 31.03.2026	Remaining as of today	Reallocated	Required
<b>Nutraceutical Division (Plot No. 59)</b>					
Land	139.00	139.00	0.00	0.00	0.00
Building & Civil Works)	787.06	537.67	249.39	0.00	1,796.37
Plant & Machineries	1,323.05	423.83	899.22	393.36	0.00
<b>Total (A)</b>	<b>2,249.11</b>	<b>1,100.50</b>	<b>1148.61</b>	<b>393.36</b>	<b>1,796.37</b>
<b>Veterinary Food Division (Plot No. 28)</b>					
Land	59.00	59.00	0.00	0.00	0.00
Building & Civil Works	679.23	0.00	679.23	429.23	0.00
Plant & Machineries	410.35	79.00	331.35	120.12	0.00
<b>Total (B)</b>	<b>1,148.58</b>	<b>138.00</b>	<b>1,010.58</b>	<b>549.35</b>	<b>0.00</b>
<b>Purchase of Machineries</b>					
Machine Purchase	275.65	74.96	200.69	66.60	0.00
<b>Total ©</b>	<b>275.65</b>	<b>74.96</b>	<b>200.69</b>	<b>66.60</b>	<b>0.00</b>
<b>TOTAL (A+B+C)</b>	<b>3,673.34</b>	<b>1,313.47</b>	<b>2,359.87</b>	<b>1,009.31</b>	<b>1,796.37</b>

**RESOLVED FURTHER THAT** the additional amount of ₹1,009.31 Lakhs (₹1,796.37 Lakhs - ₹787.06 Lakhs) required for construction of Plot No. 59 be met by:

- Reallocation of ₹429.23 Lakhs from the amount earmarked for construction of Plot No. 28; and
- Total Reallocation of ₹580.08 Lakhs from the amount earmarked for;
  - Purchase of Machineries of Nutraceutical Division amounting to ₹393.36 Lakhs;
  - Purchase of Machineries of Veterinary Food Division amounting to ₹120.12 Lakhs; and
  - Purchase of Machinery amounting to ₹66.60 Lakhs.

**RESOLVED FURTHER THAT** the Company be and is hereby authorised to engage suitable vendors for post-construction allied activities in respect of Plot No. 59 and Plot No. 28, such activities including wiring, fabrication, finishing, and other ancillary works, in substitution or addition to the vendors mentioned in the Prospectus, and to consider new vendors who provide cost-effective solutions and improved operational outcomes.



**Regd. Office :** 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.  
**Factory :** Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.  
**Contact No. :** +91 9820201063 / 8080333319 / 8411879521  
**Email :** influxhealthtech@gmail.com/ influxhealthcare1@gmail.com  
**Website :** www.influxhealthtech.com  
**CIN :** U24299MH2020PLC346825

**RESOLVED FURTHER THAT** the proposed variation in the objects of the IPO Proceeds shall be undertaken by the Company only if such variation is approved with majority of more than 90% of shareholding (present and voting and voting through remote e-voting).

**RESOLVED FURTHER THAT** in the event this resolution is approved by a majority that meets or exceeds the statutory threshold for a special resolution but does not exceed the aforesaid 90% of shareholding threshold, the Company will, notwithstanding the foregoing statutory threshold, not implement the proposed variation and such resolution shall be deemed by the Company as not having been acted upon / implemented. Accordingly, the objects of the IPO Proceeds mentioned in the Prospectus will be deemed to have not been varied and accordingly, the provisions of Regulation 59 read with Schedule XX of the SEBI ICDR Regulations relating to the exit offer by the promoter will not apply to the proposed resolution.

**RESOLVED FURTHER THAT** the Board of Directors or Company Secretary of the Company be and are hereby authorized to take all such steps and actions and to do all such acts, deeds, matters and things as may be necessary or expedient to give effect to this resolution including filing of requisite forms, intimations to Stock Exchange, and to settle any questions, difficulties or doubts that may arise in this regard.”

#### **ITEM NO. 2:**

#### **APPOINTMENT AND APPROVAL OF SITTING FEES OF MR. MOHMAD SALEH MUTVALLI (DIN: 07361078) AS INDEPENDENT DIRECTOR OF THE COMPANY:**

*To consider, and if thought fit, to pass, with or without modifications, the following resolution as a **Special Resolution**:*

“**RESOLVED THAT** pursuant to the provisions of Sections 149, 150, 152, 161, Schedule IV and other applicable provisions of the Companies Act, 2013 (“the Act”) read with the Rules framed thereunder, and applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“the SEBI Listing Regulations”) (including any statutory modification or re-enactment(s) thereof for the time being in force), the Articles of Association of the Company, approvals and recommendation of the Nomination and Remuneration Committee and that of the Board of Directors, Mr. Mohmad Saleh Mutvalli (DIN: 07361078), who was appointed as an Additional Director in the capacity of an Independent Director with effect from March 31, 2026, who meets the criteria for independence under Section 149(6) of the Act and the Rules made thereunder and Regulation 16(1)(b) of the SEBI Listing Regulations and in respect of whom the Company has received a notice in writing from a member under Section 160(1) of the Act, be and is hereby appointed as an Independent Director of the Company for a period of 5 (five) consecutive years till March 30, 2031, and that he shall not be liable to retire by rotation.

**RESOLVED FURTHER THAT** the members take note of the consent letter in the Form DIR-2, the disclosure of interest under Section 184 of the Companies Act, in the Form MBP-1 in compliance with the Rule 9 of the Companies (Meetings of Board and its Powers) Rules, 2014, received from Mr. Mohmad Saleh Mutvalli providing his consent and confirming his eligibility to act as an Independent Director of the Company.



**Regd. Office :** 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.

**Factory :** Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.

**Contact No. :** +91 9820201063 / 8080333319 / 8411879521

**Email :** influxhealthtech@gmail.com/ influxhealthcare1@gmail.com

**Website :** www.influxhealthtech.com

**CIN :** U24299MH2020PLC346825

**RESOLVED FURTHER THAT** the members take note of the declaration in writing received from Mr. Mohmad Saleh Mutvalli in Form DIR-8 confirming that he is not disqualified under Section 164 of the Companies Act from acting as a director of the Company.

**RESOLVED FURTHER THAT** the Code for Independent Directors, as prescribed under Schedule IV of the Companies Act, 2013, be and is hereby placed before the members of the Company for their information and noting, and that Mr. Mohmad Saleh Mutvalli, who has been appointed as an Independent Director, shall comply with the said Code during his tenure as an Independent Director of the Company.

**RESOLVED FURTHER THAT** the terms of appointment of the Independent Director pursuant to the provisions of the Companies Act, a draft of such terms of appointment was circulated to the members, be and are hereby approved and recorded.

**RESOLVED FURTHER THAT** any of the Directors of the Company be and are hereby authorized to do all such acts, deeds, matters and things as may be necessary, expedient and incidental to give effect to the foregoing resolution, including filing of necessary forms with the Registrar of Companies, for appointment.”

**Registered Office:**

109, Ghanshyam Enclave Premises Co-op Soc Plot No.  
856, Laljipada, Kandivali West, Mumbai - 400067  
Maharashtra, India.

**By Order of the Board of Directors of  
Influx Healthtech Limited**

**Sd/-**

**Munir Abdul Ganee Chandniwala  
Chairman and Managing Director  
DIN: 08459582**

**Date:** April 1, 2026

**Place:** Mumbai

---

**NOTES:**

1. The Explanatory Statement pursuant to Section 102 read with Section 110 of the Act and Rule 22 of the Rules setting out the material facts and reasons for the proposed Resolution of the Postal Ballot Notice is appended herein below for your consideration and forms part of this Notice.
2. In compliance with the provisions of Section 108 and Section 110 of the Act read with Rules 20 and 22 of the Rules, Regulation 44 of the Listing Regulations, SS-2 and the MCA Circulars, the Company is pleased to provide e-Voting facility to its Members, to enable them to cast their votes electronically. The Company has engaged the services of Central Depository Services (India) Limited (“CDSL”) provide e-voting facilities to its members. The instructions for e-voting are annexed to this Notice.
3. The Notice is being sent to all the Members, whose names appear on the List of Beneficial Owners as on Friday, March 27, 2026, as received from National Securities Depository Limited (“NSDL”) and Central Depository Services Limited (“CDSL”) (collectively referred to as “Depositories”). In compliance with the MCA Circulars, the Notice is being sent to Members only in electronic form to the e-mail addresses registered with their Depository Participants. Physical copies of the Notice are not being sent to the Members for this Postal Ballot. Therefore, those Members who have not yet registered their e-mail addresses are requested to get their e-mail addresses registered by following the procedure given in the e-voting instructions.
4. As per the MCA Circulars, physical copies of the Postal Ballot Notice, postal ballot forms and pre-paid business reply envelopes are not being sent to Members for this postal ballot. Members are requested to provide their assent or dissent through e-Voting only. The Company has engaged in the services of CDSL for providing e-Voting facility to its members.
5. A copy of the Postal Ballot Notice is available on the website of the Company at [www.influxhealthtech.com](http://www.influxhealthtech.com), website of the stock exchange i.e. National Stock Exchange of India Limited at [www.nseindia.com](http://www.nseindia.com) respectively and on the website of our e-Voting agency i.e. CDSL.
6. All relevant documents referred to in the Postal Ballot Notice will also be available electronically for inspection, without any fee, to Members from the date of circulation of the Postal Ballot Notice up to the closure of the voting period. Members desirous of inspecting the documents referred to in the Notice or Statement may send their requests to [cs@influxhealthtech.com](mailto:cs@influxhealthtech.com) from their registered e-mail addresses mentioning their names, DP ID and Client ID.
7. To support the ‘Green Initiative’, Members who have not yet registered their email addresses are requested to register the same with their Depository Participants.
8. The voting rights of the Members shall be in proportion to their share of the paid-up equity share capital of the Company as on the Cut-Off Date i.e. Friday, March 27, 2026. Only those members whose names appear in the List of Beneficial Owners as on the Cut-off Date shall only be considered eligible for the purpose of e-Voting and those members would be able to cast their votes and convey their assent or dissent to the proposed resolution only through the e-Voting process. Any person who is not a member as on the Cut-off date should treat this Postal Ballot Notice for information purpose only.

9. Members of the Company as on the Cut-Off Date (including those Members who may not have received this Notice due to non-registration of their e-mail addresses with the Company/RTA/Depositories) shall be entitled to vote in relation to the aforementioned resolution in accordance with the process specified in this Postal Ballot Notice. A Member cannot exercise his vote by proxy on a Postal Ballot.

10. The e-Voting details are as under:

<b>Commencement of e-voting:</b>	Thursday, April 2, 2026 at 9:00 AM (IST)
<b>End of e-voting:</b>	Friday, May 1, 2026 at 5:00 PM (IST) (both days inclusive)

During this period, members of the Company holding shares in electronic form as on the Cut-Off Date may cast their vote electronically. The e-Voting will be blocked by CDSL immediately thereafter and will not be allowed beyond the said date and time.

11. Members are requested to cast their vote through the e-Voting process not later than 5:00 p.m. IST on May 1, 2026, in order to be eligible for being considered, failing which it will be strictly considered that no vote has been received from the Member. Once the votes on the Resolution are casted by the Member, the Member shall not be allowed to change these subsequently.

12. The Board of Directors of the Company has appointed Mr. Sumitkumar Hareshbhai Patel (/Membership No.: ACS 71431), Partner of M/s. Richi Prerak & Associates, Practicing Company Secretary, as the Scrutinizer ("Scrutinizer") for conducting the Postal Ballot / e-voting process in a fair and transparent manner.

13. The Scrutinizer will submit his report to the Chairman of the Company or such person as authorized, upon completion of scrutiny of the votes received through the e-voting platform, not later than May 5, 2026. The Chairman or any person so authorized by him, shall announce the results of the Postal Ballot on or before 05:00 p.m. (IST) May 5, 2026, in accordance with the regulatory provisions.

14. The Results declared along with the Scrutinizer's Report shall be placed on the Company's website [www.influxhealthtech.com](http://www.influxhealthtech.com) and on the website of RTA immediately after the result is declared by the Chairman or any other person authorized by him, and the same shall be communicated to the Stock Exchange, where the equity shares of the Company are listed.

15. The Resolution, if approved by the requisite majority through Postal Ballot, shall be deemed to have been passed on May 1, 2026, i.e., the last date specified for receipt of votes through the e-Voting process.

#### **PROCEDURE FOR E-VOTING:**

#### **THE INSTRUCTIONS OF SHAREHOLDERS FOR REMOTE E-VOTING:**

**Step 1** : Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

**Step 2** : Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

- (i) The voting period begins on Thursday, April 2, 2026 at 9:00 AM (IST) and ends on Friday, May 1, 2026 at 5:00 PM (IST) (both days inclusive). During this period shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date (record date) of Friday, March 27, 2026 may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.
- (ii) Pursuant to SEBI Circular No. **SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 09.12.2020**, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.

In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to **all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants**. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

**Step 1:** Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

- (iii) In terms of **SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020** on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Pursuant to abovesaid SEBI Circular, Login method for e-Voting **for Individual shareholders holding securities in Demat mode CDSL/NSDL** is given below:

Type of shareholders	Login Method
<p>Individual Shareholders holding securities in Demat mode with <b>CDSL Depository</b></p>	<ol style="list-style-type: none"> <li>1) Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login to Easi / Easiest are requested to visit cdsl website <a href="http://www.cdslindia.com">www.cdslindia.com</a> and click on login icon &amp; My Easi New (Token) Tab.</li> <li>2) After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly.</li> <li>3) If the user is not registered for Easi/Easiest, option to register is available at cdsl website <a href="http://www.cdslindia.com">www.cdslindia.com</a> and click on login &amp; My Easi New (Token) Tab and then click on registration option.</li> <li>4) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on <a href="http://www.cdslindia.com">www.cdslindia.com</a> home page. The system will authenticate the user by sending OTP on registered Mobile &amp; Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.</li> </ol>
<p>Individual Shareholders holding securities in demat mode with <b>NSDL Depository</b></p>	<ol style="list-style-type: none"> <li>1) If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: <a href="https://eservices.nsd.com">https://eservices.nsd.com</a> either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period.</li> <li>2) If the user is not registered for IDeAS e-Services, option to register is available at</li> </ol>

	<p><a href="https://eservices.nsd.com">https://eservices.nsd.com</a>. Select “Register Online for IDeAS “Portal or click at <a href="https://eservices.nsd.com/SecureWeb/IdeasDirectReg.jsp">https://eservices.nsd.com/SecureWeb/IdeasDirectReg.jsp</a></p> <p>3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <a href="https://www.evoting.nsd.com/">https://www.evoting.nsd.com/</a> either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period.</p> <p>4) For OTP based login you can click on <a href="https://eservices.nsd.com/SecureWeb/evoting/evotinglogin.jsp">https://eservices.nsd.com/SecureWeb/evoting/evotinglogin.jsp</a>. You will have to enter your 8-digit DP ID,8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on <b>company name or e-Voting service provider name</b> and you will be re-directed to <b>e-Voting service provider website</b> for casting your vote during the remote e-Voting period.</p>
<p>Individual Shareholders (holding securities in demat mode) login through their <b>Depository Participants (DP)</b></p>	<p>You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period.</p>

**Important note:** Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

**Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL**

Login type	Helpdesk details
Individual Shareholders holding securities in Demat mode with <b>CDSL</b>	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 21 09911
Individual Shareholders holding securities in Demat mode with <b>NSDL</b>	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at: 022 - 4886 7000 and 022 - 2499 7000

**Step 2 :** Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

(iv) Login method for Remote e-Voting for **Physical shareholders and shareholders other than individual holding in Demat form.**

- 1) The shareholders should log on to the e-voting website [www.evotingindia.com](http://www.evotingindia.com).
- 2) Click on “Shareholders” module.
- 3) Now enter your User ID
  - a. For CDSL: 16 digits beneficiary ID,
  - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
  - c. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.
- 4) Next enter the Image Verification as displayed and Click on Login.
- 5) If you are holding shares in demat form and had logged on to [www.evotingindia.com](http://www.evotingindia.com) and voted on an earlier e-voting of any company, then your existing password is to be used.

6) If you are a first-time user follow the steps given below:

	<b>For Physical shareholders and other than individual shareholders holding shares in Demat.</b>
PAN	Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) <ul style="list-style-type: none"> <li>• Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by Company/RTA or</li> </ul>

	contact Company/RTA.
Dividend Bank Details OR Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login. <ul style="list-style-type: none"> <li>If both the details are not recorded with the depository or company, please enter the member id / folio number in the Dividend Bank details field.</li> </ul>

- (v) After entering these details appropriately, click on “SUBMIT” tab.
- (vi) Shareholders holding shares in physical form will then directly reach the Company selection screen. However, shareholders holding shares in demat form will now reach ‘Password Creation’ menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- (vii) For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- (viii) Click on the EVSN for the relevant <Company Name> on which you choose to vote.
- (ix) On the voting page, you will see “RESOLUTION DESCRIPTION” and against the same the option “YES/NO” for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- (x) Click on the “RESOLUTIONS FILE LINK” if you wish to view the entire Resolution details.
- (xi) After selecting the resolution, you have decided to vote on, click on “SUBMIT”. A confirmation box will be displayed. If you wish to confirm your vote, click on “OK”, else to change your vote, click on “CANCEL” and accordingly modify your vote.
- (xii) Once you “CONFIRM” your vote on the resolution, you will not be allowed to modify your vote.
- (xiii) You can also take a print of the votes cast by clicking on “Click here to print” option on the Voting page.
- (xiv) If a demat account holder has forgotten the login password, then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.

- (xv) There is also an optional provision to upload BR/POA if any uploaded, which will be made available to scrutinizer for verification.
- (xvi) **Additional Facility for Non – Individual Shareholders and Custodians –For Remote Voting only.**
- Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to [www.evotingindia.com](http://www.evotingindia.com) and register themselves in the “Corporates” module.
  - A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to [helpdesk.evoting@cdslindia.com](mailto:helpdesk.evoting@cdslindia.com).
  - After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
  - The list of accounts linked in the login will be mapped automatically & can be delink in case of any wrong mapping.
  - It is Mandatory that, a scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
  - Alternatively Non Individual shareholders are required mandatory to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz; [cs@influxhealthtech.com](mailto:cs@influxhealthtech.com), if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

#### **PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/DEPOSITORIES.**

1. For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to [cs@influxhealthtech.com](mailto:cs@influxhealthtech.com) / [rtaoffice@maashitla.com](mailto:rtaoffice@maashitla.com).
2. For Demat shareholders -, Please update your email id & mobile no. with your respective Depository Participant (DP)
3. For Individual Demat shareholders – Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory for e-Voting. If you have any queries or issues regarding e-Voting from the CDSL e-Voting System, you can write an email to [helpdesk.evoting@cdslindia.com](mailto:helpdesk.evoting@cdslindia.com) or contact at toll free no. 1800 21 09911.

All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Sr. Manager, (CDSL, ) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to [helpdesk.evoting@cdslindia.com](mailto:helpdesk.evoting@cdslindia.com) or call at toll free no.1800 21 09911.



**Regd. Office :** 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.

**Factory :** Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.

**Contact No. :** +91 9820201063 / 8080333319 / 8411879521

**Email :** influxhealthtech@gmail.com/ influxhealthcare1@gmail.com

**Website :** www.influxhealthtech.com

**CIN :** U24299MH2020PLC346825

**STATEMENT PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013 READ WITH RULE 22 OF THE COMPANIES (MANAGEMENT AND ADMINISTRATION) RULES, 2014 AND ADDITIONAL INFORMATION AS REQUIRED UNDER THE SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

**Item No. 1:**

**ALTERATION IN THE OBJECTS OF THE INITIAL PUBLIC OFFER (“OFFER”) FOR WHICH AMOUNT WAS RAISED:**

The Company had undertaken an Initial Public Offer in the Financial Year 2024-25 which consisted of a Fresh Issue of equity shares by the Company amounting up to Rs. 4,800.38 Lakhs (“Fresh Issue”) from the public through a Prospectus dated June 23, 2025. The Company had set out the following items as the objects towards which the IPO Proceeds would be utilised in the section “Objects of the Offer” in the prospectus prepared in connection with the Offer:

1. Funding capital expenditure requirements for setting up of manufacturing facility for Nutraceutical Division.
2. Funding capital expenditure requirements for setting up of manufacturing facility for Veterinary Food Division.
3. Purchase of Machineries for Homecare and Cosmetic Division.
4. General Corporate Purposes.

The Company now intends to alter the terms of utilisation of the IPO Proceeds. As on September 30, 2025, an amount of Rs. 3,361.47 Lakhs remains unutilized and as on the date of this notice Rs. 2,359.87 Lakhs remains unutilized out of the funds so raised i.e. Rs. 4,800.38 Lakhs primarily attributable to slow down of business under prevailing market conditions.

Subsequent to commencement of implementation of the project, the Company has undertaken a detailed review of the construction requirements and machinery procurement plan. Based on the revised technical evaluation and updated cost estimates, the total construction cost for Plot No. 59 has increased to ₹1,796.37 Lakhs as against ₹787.06 Lakhs originally estimated in the Prospectus. The increase is primarily attributable to revision in project specifications, enhanced infrastructure requirements, escalation in construction material and labour costs, and additional compliance-related structural modifications.

At the same time, the construction requirement for Plot No. 28 has been optimised and is presently estimated at ₹250.00 Lakhs as against ₹679.23 Lakhs disclosed in the Prospectus, resulting in a surplus amount of ₹429.23 Lakhs. Further, upon review of the machinery procurement plan, certain machineries are proposed to be deferred or procured in a phased manner from internal accruals, and in certain cases the Company has achieved cost optimisation. This has resulted in a surplus of ₹580.08 Lakhs, arising from the allocations originally earmarked towards (i) Purchase of Machineries in the Nutraceutical Division amounting to ₹393.36 Lakhs, (ii) Purchase of Machineries in the Veterinary Food Division amounting to ₹120.12 Lakhs, and (iii) Purchase of Machinery amounting to ₹66.60 Lakhs, respectively.

In view of the foregoing, the Board of Directors, at its meeting held on March 31, 2026, approved the reallocation of ₹429.23 Lakhs from the object relating to construction of Plot No. 28 and ₹580.08 Lakhs from the objects relating to the Nutraceutical Division, Veterinary Food Division, and purchase of machineries, towards meeting the enhanced construction cost of ₹1,796.37 Lakhs for Plot No. 59.

Further, the relevant and material information as per Rule 7 of the Companies (Prospectus and Allotment of Securities) Rules, 2014 and Rule 32 of Companies (Incorporation) Rules, 2014 is set out below:

- (a) **The original purpose or object of the Issue:**
- (b) **The total money raised:**
- (c) **The money utilised for the objects stated in the Prospectus:**
- (d) **The extent of achievement of proposed objects:**
- (e) **The unutilised amount out of the money so raised:**

*(Amount in Lakhs)*

Sr. No.	Particulars	Allocation of Fund as per Prospectus	Amount Utilised upto 31.03.2026	Extent of achievement of the proposed objects (in %)	Unutilised Amount
1.	Funding capital expenditure requirements for setting up of manufacturing facility for Nutraceutical Division	2,249.11	1,150.50	51.15	1,148.61
2.	Funding capital expenditure requirements for setting up of manufacturing facility for Veterinary Food Division	1,148.58	138.00	12.01	1,010.58
3.	Purchase of Machineries for Homecare and Cosmetic Division	275.65	74.96	27.19	200.69
4.	General corporate purposes	667.40*	667.40	100.00	0.00
	<b>Total</b>	<b>4,340.74</b>	<b>2,030.86</b>	<b>45.63</b>	<b>2359.87</b>

*\*In accordance with the terms of the Prospectus, all expenses relating to the Offer were paid by the Company in the first instance, with the Selling Shareholder agreeing to reimburse its proportionate share of such expenses from the Offer for Sale proceeds. The Company has paid ₹123.59 lakhs on behalf of the Selling Shareholder towards such expenses, which amount has subsequently been added to "General Corporate Purposes" (GCP). Consequently, the original GCP allocation of ₹543.81 lakhs as per the Prospectus has been increased to ₹667.40 lakhs by giving effect to the above adjustment.*

**(f) Particulars of the proposed variation:**

Subsequent to commencement of implementation of the project, the Company has undertaken a detailed review of the construction requirements and machinery procurement plan. Based on the revised technical evaluation and updated cost estimates, the total construction cost for Plot No. 59 has increased to ₹1,796.37 Lakhs as against ₹787.06 Lakhs originally estimated in the Prospectus. The increase is primarily attributable to revision in project specifications, enhanced infrastructure requirements, escalation in construction material and labour costs, and additional compliance-related structural modifications.

At the same time, the construction requirement for Plot No. 28 has been optimised and is presently estimated at ₹250.00 Lakhs as against ₹679.23 Lakhs disclosed in the Prospectus, resulting in a surplus amount of ₹429.23 Lakhs. Further, upon review of the machinery procurement plan, certain machineries are proposed to be deferred or procured in a phased manner from internal accruals, and in certain cases the Company has achieved cost optimisation. This has resulted in a surplus of ₹580.08 Lakhs, arising from the allocations originally earmarked towards (i) Purchase of Machineries in the Nutraceutical Division amounting to ₹393.36 Lakhs, (ii) Purchase of Machineries in the Veterinary Food Division amounting to ₹120.12 Lakhs, and (iii) Purchase of Machinery amounting to ₹66.60 Lakhs, respectively.

In view of the foregoing, the Board of Directors, at its meeting held on March 31, 2026, approved the reallocation of ₹429.23 Lakhs from the object relating to construction of Plot No. 28 and ₹580.08 Lakhs from the objects relating to the Nutraceutical Division, Veterinary Food Division, and purchase of machineries, towards meeting the enhanced construction cost of ₹1,796.37 Lakhs for Plot No. 59.

Further, For Plot No. 59 and Plot No. 28, the Company had identified certain vendors for construction activities based on estimates and discussions prevailing at the time of filing of Prospectus. However, upon commencement of project execution, the Company has reassessed its requirements and determined that the construction phase will be undertaken as originally envisaged. For post-construction allied activities - such as wiring, fabrication, finishing, and other ancillary works - the Company has evaluated multiple vendors with the objective of ensuring:

- Competitive pricing
- Timely completion of allied works
- Superior quality standards
- Localised operational efficiencies

Accordingly, the Company proposes to engage suitable vendors for allied activities, such as wiring, fabrication, and other ancillary works, in substitution or addition to those originally mentioned in the Prospectus and may also consider new vendors who offer cost-effective solutions and improved operational outcomes.

This proposed engagement does not alter the fundamental nature of the object but is intended to facilitate efficient completion of the project within revised cost parameters.

**(g) Reason and justification for seeking variation:**

The proposed variation is sought pursuant to a comprehensive reassessment of the project implementation plan and updated cost evaluations undertaken after commencement of the objects stated in the Prospectus. Based on

detailed technical review and consultations with project consultants and contractors, the estimated construction cost for Plot No. 59 has increased due to revised project specifications, strengthening of structural design, additional infrastructure requirements, compliance with applicable regulatory and safety norms, and escalation in material and labour costs. Conversely, the construction requirement at Plot No. 28 has been optimised following revised planning and operational re-evaluation, resulting in surplus funds. Further, certain machinery purchases have been deferred in line with the Company's phased expansion strategy and prevailing market conditions, and cost efficiencies have been achieved in procurement, thereby creating additional surplus under the machinery allocation.

In view of the above, the Board considers the proposed reallocation of surplus funds from Plot No. 28 and the machinery allocation towards meeting the enhanced construction requirement of Plot No. 59 to be justified, prudent and in the best interest of the Company and its stakeholders. The variation will enable timely completion of the expanded facility, ensure optimal and efficient utilisation of the IPO proceeds, and avoid the necessity of raising additional external borrowings or incurring interest costs, thereby supporting the Company's financial stability and long-term growth objectives.

**(h) Amount proposed to be utilised for the new objects:**

Pursuant to the proposed variation in the utilisation of IPO proceeds, the Company proposes to utilise a total amount of ₹1,796.37 Lakhs towards construction related expenses for Plot No. 59, being the revised project cost. Out of the said amount, ₹787.06 Lakhs represents the original allocation as disclosed in the Prospectus, ₹429.23 Lakhs is proposed to be reallocated from the funds originally earmarked for construction of Plot No. 28, ₹580.08 Lakhs is proposed to be reallocated from the funds originally earmarked towards (i) Purchase of Machineries in the Nutraceutical Division amounting to ₹393.36 Lakhs, (ii) Purchase of Machineries in the Veterinary Food Division amounting to ₹120.12 Lakhs, and (iii) Purchase of Machinery amounting to ₹66.60 Lakhs, respectively. Accordingly, an aggregate amount of ₹1,009.31 Lakhs is proposed to be additionally utilised towards the enhanced construction cost of Plot No. 59 pursuant to the approval of the Members.

**(i) The estimated financial impact of the proposed alteration on the earnings and cash flow of the company:**

The proposed variation in utilisation of IPO proceeds is not expected to have any adverse impact on the earnings or cash flows of the Company. The reallocation involves utilisation of surplus funds available under the originally stated objects and does not entail raising of additional external borrowings or incurrence of interest costs. Accordingly, there will be no incremental finance cost burden on the Company arising from the proposed alteration.

The enhanced allocation towards construction of Plot No. 59 is expected to facilitate timely completion of the expanded infrastructure, which in turn is anticipated to strengthen the Company's operational capacity and revenue-generating potential in the medium to long term. While the deferment of certain machinery purchases may temporarily stagger capital expenditure deployment, such procurement is proposed to be undertaken in a phased manner from internal accruals and is not expected to materially impact ongoing operations. Overall, the proposed reallocation is expected to result in efficient capital deployment without adversely affecting the Company's profitability or liquidity position.

**(j) Proposed time limit for achieving varied objects:**

The proposed enhanced construction on Plot No. 59 is expected to be completed within approximately 180 days from the date of approval by the Members.

**(k) Clause-wise details as specified under Rule 3(3):**

**i. Means of Finance:**

Source	Amount (₹ Lakhs)
Original Allocation – Plot 59	787.06
Reallocation – Plot 28	429.23
Reallocation – Machinery	580.08
<b>Total</b>	<b>1,796.37</b>

**ii. Schedule of Implementation:**

The proposed enhanced construction on Plot No. 59 is expected to be completed within approximately 180 days from the date of approval by the Members.

**iii. Interim use of Funds/Deployment Status:**

Funds proposed for reallocation are presently lying in bank balances pending utilisation.

**(l) Risk factors pertaining to the new objects:**

The revised allocation may involve certain risks, including potential escalation in construction costs due to inflationary pressures, possible delays in completion arising from regulatory approvals or supply chain disruptions, temporary impact on production scalability due to deferred machinery procurement, and fluctuations in market demand that may affect the projected returns from the expanded capacity; however, the Board believes that the revised allocation is commercially prudent and in the best interest of the Company.

**(m) the place from where any interested person may obtain a copy of the notice of resolution to be passed:**

Any interested person may obtain a copy of the notice of the resolution from the registered office of the Company during business hours or may access it from the Company's website [www.influxhealthtech.com](http://www.influxhealthtech.com).

**(n) Other relevant information for informed decision:**

The proposed variation does not alter the core business of the Company and does not result in any change in its overall capital structure; none of the Directors or Key Managerial Personnel is concerned or interested in the resolution except to the extent of their respective shareholding, if any, and the Board of Directors has duly approved the said variation at its meeting held on March 31, 2026.



**Regd. Office :** 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.

**Factory :** Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.

**Contact No. :** +91 9820201063 / 8080333319 / 8411879521

**Email :** influxhealthtech@gmail.com/ influxhealthcare1@gmail.com

**Website :** www.influxhealthtech.com

**CIN :** U24299MH2020PLC346825

Through its resolution dated March 31, 2026, the Board has approved the variation in objects of the Company subject to receipt of approval of majority of more than 90% of shareholding (present and voting and voting through remote e-voting) through Postal Ballot. The Company will undertake necessary implementation in relation to the variation of objects / terms of the IPO Proceeds, only if the aforesaid resolution is approved with majority of more than 90% of shareholding (present and voting and voting through remote e-voting) through Postal Ballot. Therefore, even if the statutory threshold of 75% for a special resolution is achieved, the above majority of more than 90% of shareholding is not obtained, the Company will, notwithstanding the foregoing statutory threshold, not act upon or implement the proposed variation of objects / terms of utilization will not be varied. Accordingly, the objects / terms of utilization of IPO Proceeds mentioned in the Prospectus will be deemed to have not been varied. Therefore, the exit offer under Regulation 59 read with Schedule XX of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“SEBI ICDR Regulations”) does not apply to this proposed resolution.

The Board believes that the proposed reallocation will provide necessary flexibility to efficiently utilise surplus IPO funds towards completion of the enhanced construction of Plot No. 59 without incurring additional debt. The Board is of the view that such prudent capital deployment will strengthen operational capacity and support long-term shareholder value.

None of the Directors or Key Managerial Personnel of the Company or their relatives are, in any way, concerned or interested, financially or otherwise, in the proposed resolution, except to the extent of their shareholding in the Company.

The Board accordingly recommends the Special Resolution set out at Item No. 01 of the accompanying Notice for approval of the Members.

#### **Item No. 2:**

#### **APPOINTMENT AND APPROVAL OF SITTING FEES OF MR. MOHMAD SALEH MUTVALLI (DIN: 07361078) AS INDEPENDENT DIRECTOR OF THE COMPANY:**

Pursuant to the applicable provisions of the Companies Act, 2013 read with relevant provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as applicable to SME Listed Companies, the appointment of an Independent Director is required to be approved by the Members of the Company.

With a view to comply with the above requirement and to have an optimum combination and balanced composition on the Board, the Board of Directors of the Company, subject to approval of the Members, and based on the recommendation of the Nomination and Remuneration Committee (“NRC”), after careful consideration of his profile as stated hereinafter and in terms of the Nomination and Remuneration Policy of the Company, had appointed Mr. Mohmad Saleh Mutvalli (DIN: 07361078) as an Additional Director (designated as Non-Executive and Independent Director) of the Company with effect from March 31, 2026, for a term of 5 (five) consecutive years, not liable to retire by rotation, pursuant to the provisions of Sections 149, 150, 152 and 161 of the Act and rules made thereunder.



**Regd. Office :** 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.

**Factory :** Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.

**Contact No. :** +91 9820201063 / 8080333319 / 8411879521

**Email :** influxhealthtech@gmail.com / influxhealthcare1@gmail.com

**Website :** www.influxhealthtech.com

**CIN :** U24299MH2020PLC346825

The Company has received a declaration from Mr. Mohmad Saleh Mutvalli confirming that he meets the criteria of independence as prescribed under Section 149(6) of the Act. Further, he is not disqualified from being appointed as a Director in terms of Section 164 of the Act and has not been debarred from holding the office of Director by virtue of any order passed by SEBI or any other authority. He has also registered himself in the Independent Director's Data Bank maintained by the Indian Institute of Corporate Affairs.

The Company has received a notice in writing under Section 160 of the Act from a Member proposing the candidature of Mr. Mohmad Saleh Mutvalli for the office of Independent Director of the Company, to hold office for a term of 5 (five) consecutive years and not liable to retire by rotation.

The brief profile of Mr. Mohmad Saleh Mutvalli, including his experience and qualifications, as required under applicable provisions, is provided in **Annexure I** to this Notice.

None of the Directors or Key Managerial Personnel of the Company or their relatives are, in any way, concerned or interested, financially or otherwise, in the proposed resolution, except to the extent of their shareholding, if any, in the Company.

The Board of Directors recommends the Special Resolution set out at Item No. 02 of the accompanying Notice for approval of the Members.

**Registered Office:**

109, Ghanshyam Enclave Premises Co-op Soc Plot No.  
856, Laljipada, Kandivali West, Mumbai - 400067  
Maharashtra, India.

**Date:** April 1, 2026

**Place:** Mumbai

**By Order of the Board of Directors of  
Influx Healthtech Limited**

**Sd/-**

**Munir Abdul Ganee Chandniwala  
Chairman and Managing Director**

**DIN: 08459582**

**Annexure - I**

**The Brief Details of Directors along with their Experience and Educational Qualification**  
**(As per Regulation 36(3) of SEBI (LODR) Regulations, 2015, read with Para 1.2.5 of the Secretarial**  
**Standard on General Meetings (SS-2))**  
**For Item No. 2**

<b>Sr. No.</b>	<b>Particulars</b>	<b>Information About Director</b>
1.	Name of Director	Mr. Mohmad Saleh Mutvalli
2.	DIN	07361078
3.	Designation	Independent Director
4.	Category	Non-Executive
5.	Date of Birth	31/01/1985
6.	Age	41 Years
7.	Qualification	Chartered Accountant (CA)
8.	No. of Equity Shares held in the Company, including shareholding as a beneficial owner.	NIL
9.	Brief profile/ Brief resume of the Director	Mr. Mohmad Saleh Mutvalli is a highly skilled Chartered Accountant with over 13 years of extensive experience in taxation, accounting, and compliance, along with sound knowledge of International Financial Reporting Standards (IFRS). He possesses a strong understanding of financial principles and regulatory frameworks and has consistently delivered accurate and timely financial information. He is proficient in tax planning, compliance, and advisory services for individuals and businesses, with the ability to navigate complex tax laws to optimize liabilities and maximize savings. His expertise also includes financial reporting, budgeting, and analysis, supported by a thorough understanding of accounting practices. Additionally, he has strong capabilities in compliance and regulatory affairs, ensuring adherence to applicable laws and corporate governance standards. A detail-oriented and analytical professional, he demonstrates strong communication and interpersonal

		skills, works effectively in team environments, and maintains a results-driven approach focused on improving financial performance and driving organizational growth. He qualified as a Chartered Accountant in May 2011 and seeks to leverage his expertise in a dynamic professional environment.
10.	In case of independent directors, the skills and capabilities required for the role and the manner in which the proposed person meets such requirements.	Mr. Mohmad Saleh Mutvalli possesses strong expertise in accounts, taxation, and financial compliance, with over 13 years of experience, including proficiency in financial reporting (IFRS), tax planning, regulatory compliance, and financial analysis, enabling him to effectively contribute to financial oversight and strategic decision-making.
11.	Terms and conditions of appointment	As per the terms of Appointment letter
12.	Date of first appointment	March 31, 2026
13.	Directorships held in other Companies, including listed entities from which the person has resigned in the last 3 years	<ol style="list-style-type: none"> <li>1. DRPL Captive Hybrid Private Limited</li> <li>2. CGE Hybrid Energy Private Limited</li> <li>3. Shubh Wind Power Private Limited</li> <li>4. Srijan Renewables Private Limited</li> <li>5. Srijan Energy Systems Private Limited</li> <li>6. Bhuj Wind Energy Private Limited</li> <li>7. Jamnagar Renewables Private Limited</li> <li>8. Morjar Windfarm Development Private Limited</li> <li>9. Jamnagar Renewables Two Private Limited</li> </ol>
14.	Particulars of Committee Chairmanship / Membership held in other Indian Companies	NIL
15.	Relationship with other Directors inter-se	-
16.	No. of Board Meetings attended during the Financial Year 2025-26	-
17.	Sitting fees Proposed to be Paid	<ul style="list-style-type: none"> <li>➤ Rs. 10,000/- (Rupees Ten Thousand Only) per Board Meeting</li> <li>➤ Rs. 5,000/- (Rupees Five Thousand Only) per Committee Meeting</li> </ul>
18.	Remuneration last drawn	-



**Regd. Office :** 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.

**Factory :** Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.

**Contact No. :** +91 9820201063 / 8080333319 / 8411879521

**Email :** influxhealthtech@gmail.com/ influxhealthcare1@gmail.com

**Website :** www.influxhealthtech.com

**CIN :** U24299MH2020PLC346825

---

**Registered Office:**

109, Ghanshyam Enclave Premises Co-op Soc Plot No.  
856, Laljipada, Kandivali West, Mumbai - 400067  
Maharashtra, India.

**Date:** April 1, 2026

**Place:** Mumbai

**By Order of the Board of Directors of  
Influx Healthtech Limited**

Sd/-

**Munir Abdul Ganee Chandniwala  
Chairman and Managing Director**

**DIN: 08459582**